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the CC BY-NC-ND license (http://creaAbstract Objective: Inflammatory serum markers have proven to be a powerful predictive
tool of patient prognosis in cancer treatment for a wide variety of solid organ malignancies,
predominantly in the context of localized disease. In this study we evaluated the preoperative
neutrophil-to-lymphocyte ratio (NLR) as a predictive tool in patients with metastatic clear cell
renal cell carcinoma (RCC).
Methods: Sixty-four patients with metastatic clear cell RCC undergoing nephrectomy were
selected. Only patients with preoperative NLR were included for survival analysis. Patients
were categorized into high and low NLR score determined by plotting the NLR ROC curve.
Multivariable analysis was performed.
Results: Median age was 60.8 years (38.2e81.2). Median follow-up time was 8.1 months (0.1
e106.3). Fuhrman grade distribution was: 2 (3.1%) grade 1, 6 (9.4%) grade 2, 24 (37.5%) grade 3
and 32 (50.0%) grade 4. Median NLR score was 3.5 (1.4e31.0). NLR  4 was associated with
decreasedoverall survival compared toNLR< 4 (pZ0.017).Multivariable survival analysis showed
NLR  4 as an independent predictor of survival (Hazard ratio (HR) 2.41, 95%CI 1.05e5.50,
pZ 0.03).
Conclusion: Elevated preoperativeNLR is associatedwith poor prognosis in patientswithmetasta-
tic kidney cancer. Preoperative NLR is a useful tool, which can predict prognosis, stratify patients
for postoperative surveillance, and help guide decisions for therapy.u (V.A. Master).
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by-nc-nd/4.0/).Figure 1 Flow chart of patients who met study inclusion/
exclusion criteria. RCC, renal cell carcinoma.1. Introduction
Renal cancer is among the 10 most common cancers in the
United States, with 63,920 new cases and 13,860 deaths
estimated in 2014 [1]. Approximately 30% of patients with
apparent localized disease will ultimately develop metas-
tasis with a 5-year survival rate of less than 10% [2,3]. As
such, there has been a tremendous, long-standing interest
in accurately identifying those patients most likely to suffer
from disease progression. Research in recent years has
focused on the development of prognostic models to aid in
surveillance strategies and patient counseling. Currently,
the most commonly used tool to predict outcome in renal
cell carcinoma (RCC) is the TNM staging system and nuclear
grade [4]. However, there is considerable overlap in sur-
vival between stages [2], which has promoted the search
for new prognostic markers to better stratify patients with
expected poor outcomes.
In past years, efforts at identifying markers of disease
progression in RCC have focused on the available and cost-
effective preoperative laboratory blood tests. It is
becoming increasingly clear that cancer progression de-
pends on a coordinated interface between tumor biology
and the host inflammatory response [5].
The systemic inflammatory response, which is usually
measured by blood-based parameters, such as C-reactive
protein, neutrophil or platelet count, among others has
been shown to independently predict the clinical outcome
of various human cancer types [6]. With the context of
genitourinary malignancies elevated neutrophil-to-
lymphocyte ratio (NLR) has been associated with high T
stage and worse survival in a variety of tumor types
including bladder and kidney cancer [7]. Of these inflam-
matory parameters, an increased NLR has been proposed as
an easily accessible and reliable marker to predict cancer
survival [6]. Increasing evidence in metastatic RCC suggests
that a high NLR might represent an independent adverse
prognostic factor in interferon treated [8], interleukin-2-
treated [9], as well as in sunitinib-treated [10] patients.
Therefore, the aim of our study is to provide further evi-
dence of the prognostic significance of the preoperative
NLR in metastatic clear cell RCC and to evaluate whether
this parameter provides additional prognostic information
[11].
2. Patients and methods
2.1. Patients
A total of 1871 patients underwent nephrectomy at Emory
University Hospital for renal tumors between 2004 and
2014. The database contains information on the de-
mographics, pathological findings, preoperative laboratoryparameters and survival of consecutive patients. Inclusion
criteria consisted of clear cell histology and radiological or
histopathological evidence of distant metastases at the
time of intervention, available preoperative NLR measure-
ments, and no concomitant immunosuppression therapy.
We chart reviewed the medical records of 81 patients
following cytoreductive nephrectomy for confirmed meta-
static RCC and all clinical records, including follow-up.
Seventeen patients with non-clear cell RCC were excluded
from the study. Consequently, the remaining 64 patients
were included in the present study (Fig. 1). The Institu-
tional Review Board approved the study.
2.2. Clinical and laboratory assessment
The clinical variables recorded included age, gender, race,
ethnicity, date of intervention, surgical approach (open vs.
laparoscopic), Eastern Cooperative Oncology Group (ECOG)
performance status, body mass index (BMI), obesity
(BMI  30 kg/m2), neutrophil count, lymphocyte count,
preoperative NLR. NLR within 1 month prior to the inter-
vention was used for analysis. All the clinicopathologic data
were retrieved from medical records of the Department of
Urology, as well as from the pathology reports from the
Department of Pathology at Emory University Hospital.
The pathologic features studied included histologic
subtype classified according to the Union for International
Cancer Control, American Joint Committee on Cancer, and
Heidelberg guidelines, tumor size, the 2009 primary tumor
and regional lymph node classifications, nuclear grade,
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was initially based on six stages (T1a, T1b, T2, T3a, T3b,
and T3c). However, one-way analysis of variance demon-
strated no significant difference in outcomes between T1a
and T1b and between T3a, T3b and T3c. Therefore, pa-
tients were divided into two groups based on low and high
T-stages: T1e2 and T3e4, respectively.
Lymph node dissection was performed at the discretion
of the treating surgeon at the time of nephrectomy. Dates
of death were obtained from United States National death
index (http://www.cdc.gov/nchs/ndi.htm), as well as from
hospital medical records and the hospital tumor registry.
Overall survival (OS) time was defined as time (in months)
from the date of surgery to the individual’s death from any
cause.
2.3. Outcome measures
OS was the primary endpoint. Metastases were diagnosed
radiologically using computerized tomography and/or
magnetic resonance imaging. Postoperative clinical evalu-
ations were generally performed every 3e6 months for the
first 5 years at the discretion of the treating physician and
then annually.
2.4. Statistical analysis
The primary study endpoint was OS, calculated as the
months from the date of the surgery to the date of death
from any cause. Cox proportional analyses were used to find
the ideal cut-off value for the continuous NLR by testing all
possible cut-offs that would discriminate between survival
and death from any cause, which was then rounded to
clinically relevant values. The relationship between NLR
and other clinicopathologic parameters was tested with
nonparametric tests. KaplaneMeier method and logerank
test were used to test the clinical endpoints. Variables in
univariate analysis with p  0.1 were included in multi-
variate analysis. We decided a priori to include age, T
stage, and grade in the multivariate analysis, irrespective
of its significance in univariate analysis, as these important
factors are used very often in prognostication schemes.
Backward stepwise multivariate Cox proportional analysis
was performed to determine the influence of pathologic T
stage, grade, age, gender, and tumor necrosis on OS after
the models were assessed for co-linearity and interactions.
Hazard ratio (HR) estimated from Cox analysis was reported
as relative risks with corresponding 95% confidence in-
tervals (CI). All statistical analysis was performed using SAS
v9.3 (SAS Institute, Cary, NC, USA). Statistical significance
in this study was set at p < 0.05.
3. Results
Sixty-four patients were included in the analysis. The study
population was 78.13% Caucasian and 72.58% males. Median
age at the time of surgery is 60.8 year (38.2e81.2). About
23.44% of the patients had BMI greater than 30 kg/m2.
Pathologic T stage was pT1eT2 in 9 (14.06%) and pT3eT4 in
55 (85.94%) of the patients while Fuhrman tumor grading
was G1eG3 in 32 (50.00%) and G4 in 32 (50.00%) of patients.Overall, histologic necrosis was noted in 31 patients. The
median neutrophil count was 5.608  109/L, median
lymphocyte count was 1.659  109/L and median NLR was
3.5 (minemax 1.4e31.0). Patients’ demographic and
pathological characteristics are summarized in Table 1. Cox
proportional analysis of NLR as a dichotomous variable
confirmed a cut point of 4 as the strongest prognostic value
in our dataset. Therefore, this level was chosen for further
analysis. At baseline, 26 (40.6%) patients had NLR greater
than or equal to 4, whereas 38 (59.4%) patients had NLR
lower than 4. Most of the baseline characteristics did not
significantly differ according to these groups, apart from
the significant association of histologic sarcomatoid change
in the tumor with a higher NLR. Of the 64 patients included
in the analysis, sunitinib, temsirolimus, pazopanib, sor-
afenib and bevacizumab were given to 21 (32.8%),
8 (12.5%), 6 (9.3%), 5 (7.8%) and 3 (4.7%) patients, respec-
tively. Two (3.1%) patients received interleukin-2, 1 (1.6%)
patient received axitinib and 1 (1.6%) patient was given
carboplatin/paclitaxel. The other 17 (26.5%) patients had
no post-cytoreductive nephrectomy therapy due to patient
preference or reasons not recorded in the clinical chart.
Survival analysis was conducted to investigate if NLR is
associated with clinical outcome of metastatic clear cell
RCC. Median follow-up time from the surgery was 8.1
months. Thirty-five patients died during the follow-up
period. Univariate analysis identified an NLR of 4 as a sig-
nificant prognosticator of poor outcome for patient OS
(p Z 0.017). Since there were only a small number of pa-
tients with low grade, low stage (pathologic T1eT2, low
histologic grade, no necrosis) disease, these variables
cannot be significantly associated with OS. One-year sur-
vival rate for the cohort was 49.0%  11.0%, while 3-year
survival rate was 17.5%  10.5%.
To determine the independent prognostic significance of
the NLR for OS, we a priori decided to include pathologic T
stage, histologic grade of the tumor, and age at surgery, as
covariates for multivariable survival analysis using Cox
proportional hazards model. In our multivariate analysis,
only NLR of 4 was found to be significantly and indepen-
dently associated with OS (HR Z 2.41; 95%CI 1.05e5.50;
pZ 0.036) (Table 2). KaplaneMeier curves stratified by low
and high NLR group are shown in Fig. 2.
4. Discussion
The outcome of patients with RCC is remarkably hetero-
geneous, and its diagnosis at an early stage remains a sig-
nificant challenge. Up to 30% of patients with localized
kidney cancer will experience recurrence. These patients
are typically treated with non-curative therapies such as
targeted therapies including tyrosine kinase inhibitor (TKI),
mammalian target of rapamycin inhibitor (mTORi) and
recently targeted immunotherapy. Despite recent progress
in the identification of genetic and molecular alterations,
the routine diagnostic and prognostic assessment of RCC
currently relies on pathological tissue examination and
traditional clinicopathological prognostic variables. There-
fore, numerous studies have focused on identifying various
objective measures, for both diagnostic as well as prog-
nostic use, to define risk groups for preoperative patient
Table 1 Clinical and pathological parameters in patients with metastatic ccRCC and low (<4) or high (4) NLR.
Covariate Level High NLR (n Z 26) Low NLR (n Z 38) Total (n Z 64) p-Value#
Gendera Female 6 (24) 11 (29.73) 17 (27.42) 0.620
Male 19 (76) 26 (70.27) 45 (72.58)
Race Other 5 (19.23) 9 (23.68) 14 (21.88) 0.672
White 21 (80.77) 29 (76.32) 50 (78.13)
Age (year) 60.6 (38.2e78.5) 62.2 (41.1e81.2) 60.8 (38.2e81.2) 0.547
BMI  30 kg/m2 No 21 (80.77) 28 (73.68) 49 (76.56) 0.511
Yes 5 (19.23) 10 (26.32) 15 (23.44)
T stage pT1eT2 1 (3.85) 8 (21.05) 9 (14.06) 0.052
pT3eT4 25 (96.15) 30 (78.95) 55 (85.94)
Grade G1eG3 10 (38.46) 22 (57.89) 32 (50.00) 0.127
G4 16 (61.54) 16 (42.11) 32 (50.00)
Necrosisa No 1 (5.26) 9 (40.91) 10 (24.39) 0.008
Yes 18 (94.74) 13 (59.09) 31 (75.61)
SSIGN score 9 (5e10) 9 (2e12) 9 (2e12) 0.571
Max tumor size 11.3 (2e16) 9 (0.9e16.1) 9.5 (0.9e16.1) 0.030
Follow-up (month) 6.9 (1.0e48.4) 11.1 (0.1e106.3) 8.1 (0.1e106.3) 0.138
Neutrophil count (  109/L) 8.608 (4.380e22.878) 4.957 (2.583e14.212) 5.608 (2.583e22.878) <0.001
Lymphocyte count (  109/L) 1238.5 (582e3230) 1880 (738e4180) 1659 (582e4180) 0.004
NLR 6.0 (4.1e31.0) 2.7 (1.4e4) 3.5 (1.4e31.0) <0.001
Values expressed as median (minemax) and n (%) # Chi-square and Wilcoxon sum rank test.
NLR, neutrophil-to-lymphocyte ratio; ccRCC, clear cell renal cell carcinoma; SSIGN, tumor stage, size, grade and necrosis.
a Numbers may not add up due to missing data.
Neutrophil-to-lymphocyte elevation appears associated with decreased overall survival in patients 23counseling and postoperative surveillance strategies in pa-
tients with metastatic RCC [12e16].
In 1999, Motzer et al. [17] utilizing a series of 670 pa-
tients treated with a wide range of therapy regimens
developed a prognostic model based on the absence of
prior nephrectomy and a series of factors including Kar-
nofsky performance status, serum lactate dehydrogenase,
hemoglobin, and corrected serum calcium. However that
was during the era before targeted therapy. Today, patients
are treated with targeted therapy worldwide. Therefore, in
2009 and then in 2014, Heng et al. [18,19] published a new
prognostic model in the new environment for clinical trials
development and patient care in patients with metastatic
RCC. The model was partially based on the MSKCC (Memo-
rial Sloan-Kettering Cancer Center) criteria [20] which
included hemoglobin, corrected serum calcium, KarnofskyTable 2 Univariate and multivariate regression models.
Univariate Multivariate
HR (95%CI) p-Value HR (95%CI) p-Value
NLR  4 2.29
(1.14e4.63)
0.017 2.41
(1.05e5.50)
0.036
Age  65
years
0.89
(0.46e1.74)
0.744 0.74
(0.34e1.59)
0.448
Gender 2.59
(1.10e6.09)
0.024 2.33
(0.90e6.02)
0.079
Tumor
stage
1.68
(0.65e4.35)
0.281 0.98
(0.34e2.79)
0.978
Grade 1.00
(0.51e1.95)
0.996 1.30
(0.63e2.65)
0.469
NLR, neutrophil-to-lymphocyte ratio.performance status and less than 1 year between initial
diagnosis and initiation of therapy. Additionally, absolute
neutrophil and platelets count were added to the model.
They showed that patients who underwent a cytoreductive
nephrectomy had a higher OS respect to patients not
receiving a cytoreductive nephrectomy (20.6 vs. 9.6
months) and it was associated to a better progression-free
survival (HR Z 0.75; 95%CI Z 0.66e0.85; p Z 0.001). The
Heng criteria have been used and validated by many other
groups [21e24]. While these criteria are of significant
value, it is possible that even simpler models can be
implemented in the prognostication of metastatic RCC pa-
tients, especially in busy clinical environments.Figure 2 KaplaneMeier curve for overall survival among
patients with metastatic clear cell RCC with high ( 4) vs. low
(< 4) NLR. NLR, neutrophil-to-lymphocyte ratio; RCC, renal
cell carcinoma.
24 Y.S. Baum et al.The systemic inflammatory response, such as C-reactive
protein, neutrophil, and platelet count, has been shown to
be independent predictors of clinical outcome of various
cancer types including gastrointestinal, soft tissue
sarcoma, nasopharyngeal and lung cancer. Of those
inflammatory-based parameters, an increased NLR
has been proposed as an easily calculated, accessible to
almost all clinicians, reliable, and low-cost marker
to predict cancer survival [6]. Previous groups have
examined pretreatment NLR in RCC patients. In a large
European cohort of 678 patients with non-metastatic
clear cell RCC, Pichler et al. [25] demonstrated that an
increased NLR was an independent negative predictor
for patient OS (HR Z 1.59; 95%CI Z 1.10e2.31;
p Z 0.014), but not a predictor for direct cancer-related
end points such as cancer specific survival (CSS)
(HR Z 1.59; 95%CI Z 0.84e2.99; p Z 0.148) and
metastatic-free survival. Our study differs from Pichler
et al. [25] because it focuses purely on metastatic pa-
tients. In 2010 and 2012, Ohno et al. [26,27] demonstrated
the prognostic role of pre- and post-treatment NLR in
localized and metastatic RCC patients who underwent
radical nephrectomy and the association between post-
operative NLR and recurrence-free survival. Recently,
Santoni et al. [28] demonstrated in a retrospective analysis
of 97 patients with metastatic RCC that pre-treatment NLR
was an independent prognostic factor (HR Z 2.27; 95%
CI Z 1.57e5.57; p < 0.001) as well as increased pre-
treatment NLR was significantly associated with worse
progression-free survival and OS in the overall population
and in the cohorts of patients treated with second- or
third-line everolimus after vascular endothelial growth
factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)
therapy. Our study showed the same conclusions regard-
less of the post-cytoreductive nephrectomy treatment. In
addition, Kobayashi et al. [29] showed in a prospective
study that changes in NLR during the early phase of tar-
geted therapy may be a strong discriminator of who will
benefit from subsequent treatment with targeted therapy.
Patients who sustained low NLR at their baseline during
the initial course of treatments could expect a more
favorable outcome in the sequential targeted therapy.
We have shown that preoperative measurement of NLR is
an independent prognostic factor of outcome of patients
who have metastatic renal cancer undergoing cytoreduc-
tive nephrectomy. That can be incorporated in counseling
about expected outcome as well as consideration of new
clinical trial design base upon systemic inflammatory
markers.
This calculation can be used in real-time clinical prac-
tice to help patients and health care providers to make a
decision proceeding with surgical therapy.
To our knowledge, there is no study that analyzes pre-
dictive associations of NLR with overall mortality in pa-
tients with metastatic clear cell RCC, regardless of the
patient’s postoperative treatment. Multivariate survival
analysis showed that preoperative NLR  4 was indepen-
dently and significantly associated with an increased risk of
overall mortality in patients with metastatic clear cell RCC
undergoing cytoreductive nephrectomy. In univariate and
multivariate analysis, we were not able to show indepen-
dent prognostic effect of pathologic T stage and gradebecause of the minimal number of patients in lower stage
and grade. Additional studies should focus on the reliable
and cost-effective prognostic markers.
Nonetheless, there are limitations to this study. First,
this is a retrospective study, which is susceptible to bias in
data selection and analysis. It is a small cohort as it
included patients with metastatic clear cell RCC only. This
study warrants validation in large multicenter trials. No
data were available about the cause of death for calcula-
tions of CSS, but given the overall diagnosis of metastatic
RCC, it is likely almost all patients would have died of RCC.
In addition, the effect of specific targeted therapy was not
investigated in this study. The patients were treated with a
large variety of therapy regimens. All of those are modern
targeted therapy treatments. While heterogeneous array of
therapies is a study limitation, this study represents a real-
time, busy clinical practice with a diverse patient popula-
tion regardless of postoperative therapy. The strength of
this study is that we have only focused on patients with
metastatic RCC, while other studies have had a focus on
localized disease.
5. Conclusion
In conclusion, preoperative NLR appears to be an inde-
pendent survival predictor in patients with metastatic RCC
undergoing cytoreductive nephrectomy. A high serum level
of NLR is associated with poor prognosis. Ultimately, the
results suggest that preoperative NLR may be useful in
patients risk stratification, postoperative surveillance, pa-
tient counseling and planning therapy strategies [15].Conflicts of interest
The authors declare no conflict of interest.References
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